2014•Critical CareOpen access

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs

Markus Honickel, Oliver Grottke, Joanne van Ryn, Hugo Ten Cate, Rolf Rossaint, Henri M.H. Spronk

Abstract

The reversal of the anticoagulant effects of the new oral anticoagulants in severely bleeding patients requires new therapeutic strategies. This study investigated the effectiveness of a specific antidote for idarucizumab to reverse bleeding in a dabigatran anticoagulated pig trauma model.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Dabigatran, Idarucizumab, Medicine, Antidote, Anesthesia, Intensive care medicine, Blood loss, Prothrombin complex concentrate